Yarbrough Capital’s CRISPR Therapeutics CRSP Stock Holding History

Yarbrough Capital’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-8,399	Closed	-$331K	–	198
2024 Q4	$331K	Hold	8,399	–	–	0.01%	161
2024 Q3	$395K	Hold	8,399	–	–	0.02%	155
2024 Q2	$454K	Sell	8,399 -100	-1%	-$5.78K	0.02%	134
2024 Q1	$579K	Hold	8,499	–	–	0.03%	120
2023 Q4	$532K	Hold	8,499	–	–	0.03%	123
2023 Q3	$386K	Hold	8,499	–	–	0.02%	149
2023 Q2	$477K	Hold	8,499	–	–	0.03%	139
2023 Q1	$384K	Buy	8,499 +8,399	+8,399%	+$408K	0.03%	153
2022 Q4	$4.07K	Buy	+100	New	+$5.3K	﹤0.01%	218
2022 Q1	–	Sell	-24,100	Closed	-$1.83M	–	213
2021 Q4	$1.83M	Buy	+24,100	New	+$2.11M	0.1%	86

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Yarbrough Capital's CRSP Position: Q1 2025 in Review

Yarbrough Capital sold out of CRISPR Therapeutics (CRSP) in Q1 2025, closing a stake of 8,399 shares — an estimated $331K sold.

Yarbrough Capital first reported a position in CRSP in Q4 2021 and held it in 10 quarters. The position peaked at $1.83M in Q4 2021. 396 funds tracked by Wall St. Rank hold CRSP as of Q1 2025.

Yarbrough Capital reported no remaining CRISPR Therapeutics position as of Q1 2025 after selling out during the quarter.
Yarbrough Capital sold 8,399 CRISPR Therapeutics shares in Q1 2025, an estimated $331K.
Yarbrough Capital first reported a position in CRISPR Therapeutics in Q4 2021 and held it in 10 quarters.
Yarbrough Capital's CRISPR Therapeutics position peaked at $1.83M in Q4 2021.
396 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2025.

Based on Yarbrough Capital's 13F filing for Q1 2025, filed 14 Apr 2025.